SAHPRA Approves Pfizer’s Paxlovid COVID-19 Treatment
SAHPRA announced the registration of Paxlovid COVID-19 treatment, an anti-viral medicine manufactured by Pfizer, to treat COVID-19. This is a 5-day oral treatment for mild to moderate COVID-19 in adults who do not require supplemental oxygen and who are at increased risk for progression to severe COVID-19.
International sources provide guidelines regarding prescribing in liver and kidney disease as well as possible drug interactions including statin therapy, anticoagulation and some hormonal birth control treatments.
Recent Posts
Global Growth and Challenges in Pharmacy Vaccination Training
Pharmacy Vaccination Training has expanded rapidly worldwide, with the number of countries offering pharmacist vaccination programs rising from 12 in 2016 to 64 by 2024. This 433 percent growth means training is now available in every nation where pharmacists may administer vaccines, including pr...
Key Strategies in Neonatal Infection Management: Insights from NICE Guideline NG195
The NICE guideline NG195 establishes a structured framework for neonatal infection management in newborns up to 28 days corrected gestational age, treating at-risk pregnant individuals, and managing suspected or confirmed infections in neonates. It emphasizes timely recognition to avoid delays, j...
Merck Oncology Advancements Highlight Long-Term Data and Pipeline Progress at ASCO 2026
Merck oncology advancements continue to deliver meaningful progress for patients. New long-term data from multiple trials highlight sustained survival benefits across lung cancer, breast cancer, melanoma, and other tumor types. These advancements will feature prominently at the 2026 American S...